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Mutation of the p53 tumour suppressor gene has been reported in
20–40% of invasive breast cancer (Runnebaum et al, 1991; Coles
et al, 1992; Sjogren et al, 1996). Mutant p53 protein accumulates
in the nucleus of neoplastic cells. Autoantibodies against p53
protein (p53 AAb) were detected in sera of breast cancer patients
in 5–26% (Schlichtholz et al, 1992; Angelopoulou et al, 1994;
Mudenda et al, 1994; Peyrat et al, 1995). In invasive breast cancer,
the presence of p53 AAb is associated with parameters of poor
prognosis such as high nuclear grade and absence of hormone
receptors (Mudenda et al, 1994; Peyrat et al, 1995). For patients
with breast, colorectal and lung tumours, the specificity of p53
AAb for malignancy is close to 100% (Crawford et al, 1982;
Winter et al, 1992; Angelopoulou et al, 1997).
Ductal carcinomas in situ (DCIS) of the breast represent about
20% of all breast carcinomas diagnosed by mammographic
screening (Schnitt et al, 1988). Nearly 95% of DCIS are detected
because of microcalcifications (Peeters et al, 1989). A palpable
breast lump develops when there is fibrotic tissue around the DCIS
lesion (Silverstein, 1997). Poorly differentiated DCIS often exhibit
branching or coarse-granular microcalcifications. Fine granular
microcalcifications are associated with well differentiated DCIS,
but they appear similar to microcalcifications of benign lesions
(Holland and Hendriks, 1994). A simple serum test with a high
specificity for malignancy could help to decide about invasive
diagnostic steps. The objective was to determine the prevalence of
p53 AAb in preoperative sera of patients with DCIS and to relate
p53 AAb status with age, clinical presentation, DCIS subtype,
tumour size, grading, p53 immunohistochemisry (IHC) and
hormone receptor status.
PATIENTS AND METHODS
Patients
From April 1995 to October 1996, 53 subsequent patients under-
went at least excisional biopsy for DCIS at the Department of
Obstetrics and Gynaecology, University of Ulm. Serum of 43
patients with histologically diagnosed DCIS of the breast was
available for analysis. Sera were collected preoperatively and were
stored at –80°C. By routine mammography 26 patients had suspi-
cious areas with granular microcalcifications, one patient demon-
strated a suspicious dense lesion. Thirteen patients presented with
a palpable breast lump and three patients complained of nipple
discharge. Two patients had previously been treated for invasive
breast cancer of the contralateral breast. The median age of the
patients was 52 years ranging from 26 to 86 years.
Serological analysis
p53 AAb were measured in serum using a sandwich enzyme-
linked immunosorbent assay (ELISA) with microtitre plates
coated with recombinant human p53 protein expressed in
Escherichia coli (Dianova, Hamburg). Compared to control sera
supplied by the manufacturer, results were categorized as negative,
low, medium and high level.
Histology
Formalin-fixed, paraffin-embedded tissue samples from all 43
patients were analysed. Nuclear grade was defined as grades 1–3
according to previously described criteria (Lagios, 1990). The
histological subtype was classified in comedo and noncomedo
subtype.
Immunohistochemistry
Tumour cell staining for p53 protein was performed with the
monoclonal antibody DO-1 (Dianova, Hamburg). Immunostaining
for oestrogen (ER) and progesterone receptors (PR) was
performed with the monoclonal antibodies ID-5 (Immunotech,
Hamburg) and 1A-6 (Dako, Hamburg) respectively. For semiquan-
titative assessment, immunohistochemical staining for nuclear p53
of more than 10% of the tumour cells was interpreted as positive.
Hormone receptor status was scored according to an immuno-
reactive score assessing the proportion of stained cells and the
staining intensity (Remmele and Stegner, 1987).
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RESULTS
p53 AAb were detected in serum of 5/43 patients (11.6%) with
DCIS, three of which had lesion sizes ≤ 5 mm. p53 AAb titre was
low in all five sera compared with assay control samples. The two
patients previously treated for invasive breast cancer had negative
test results in the ELISA. p53 AAb status with regard to clinical
and histopathological parameters are presented in Table 1. Tumour
samples were evaluable for immunohistochemistry from 30/43
patients due to the small size of the tumour tissue. Expression of
ER and PR was analysed in 29 and 27 patients respectively. In 23
cases of non-disseminated lesions, the size ranged from 3 to
90 mm (mean 21 mm). In the 20 patients with disseminated DCIS
lesions the tumour size could not be exactly determined. Nuclear
grade could be assessed in 21/43 tumours due to the heterogeneity
of the tissue. Clinical presentation and histopathological data of
p53 AAb-positive patients are listed in Table 2. No association of
p53 AAb status with age, clinical presentation, tumour size,
grading, p53-IHC, hormone receptor status and histological
subtype was observed. Only one of nine patients with comedo
subtype DCIS was positive for p53 AAb with > 90% p53-positive
tumour cells.
DISCUSSION
The prevalence of p53 AAb in our cohort of patients with DCIS
(11.6%) was comparable to the prevalence found in invasive
breast cancer which varied from 5% to 26% (Schlichtholz et al,
1992; Angelopoulou et al, 1994; Mudenda et al, 1994; Peyrat et al,
1995). In a population-based study (n = 237) we found an overall
prevalence of 16.5% in patients with invasive breast cancer using
the same test system as in this study (unpublished data). In a
previous study applying an ELISA technique and testing 182
newly diagnosed breast cancer patients, 8/23 (35%) patients with
DCIS had p53 AAb (Mudenda et al, 1994). Our ELISA assay was
tested on 41 healthy blood donors in another study, all of which
were negative for p53 AAb (Maass et al, 1996). This demonstrates
the high specificity for malignancy. The variation in the reported
p53 AAb prevalences may be explained by the different tech-
niques applied such as ELISA, immunoprecipitation or immuno-
blot (Angelopoulou et al, 1994; Mudenda et al, 1994; Peyrat et al,
1995). It may also be due to different clinical stages within the
study populations. Interestingly, in our study p53 AAb were
detected in patients with tumour lesions of 3 mm and 5 mm.
Therefore, p53 AAb immunogenicity of breast cancer cells was
not associated with extended lesions. Two patients with p53 AAb
had no p53 protein expression in the tumour. This observation was
also made in a previous study (Mudenda et al, 1994) with five of
23 seropositive breast cancer patients who had no detectable p53
accumulation in the tumour. In these patients, the immunogenic
reaction may have occurred earlier in tumour development or
factors other than accumulation such as the type of p53 mutation
or complex formation between p53 and a 70 kDa heat shock
protein contributed to the p53 AAb production (Davidoff et al,
1992). p53 AAb can already be present in patients with early, non-
palpable lesions. Given the high specificity for malignancy, the
p53 AAb ELISA may become a helpful tool in the diagnostic
process in subsets of DCIS patients to be defined in further studies.
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Table 1 Clinical and histopathological parameters with regard to p53 AAb
status
p53 AAb-positive
Parameters n (%)
Age
< 50 years 3/21 (14.3%)
³ 50 years 2/22 (9.1%)
Clinical presentation
Palpable lump 2/13 (15.4%)
Microcalcifications 3/27 (11.1%)
Nipple discharge 0/3 (0%)
p53 Immunohistochemistry
Positive 3/11 (27.3%)
Negative 2/19 (27.7%)
Hormone receptor status
ER positive 3/19 (15.8%)
ER negative 2/10 (20.0%)
PR positive 3/14 (21.4%)
PR negative 2/13 (15.4%)
Histological grading
G1 0/1 (0%)
G2 4/18 (22.2%)
G3 1/2 (50.0%)
Histological subtype of DCIS
Comedo 1/9 (11.0%)
Non-comedo 4/19 (21.1%)
Tumour size
≤ 10 mm 3/10 (30.0%)
> 10 mm 1/13 (7.7%)
Disseminated lesions 1/20 (5.0%)
Table 2 Clinical and histopathological data of p53 AAb-positive patients
No. Clinical presentation Tumour size Grading Subtype p53 IHC ER/PR
1 Palpable lump 3 mm G2 Non-comedo positivea positiveb
2 Microcalcifications 5 mm G2 Non-comedo positive positive
3 Microcalcifications 3 mm G2 Non-comedo negative positive
4 Palpable lump 25 mm G2 Non-comedo negative negative
5 Microcalcifications Disseminated small lesions G3 Comedo positive negative
aMore than 10% positive tumour cells in IHC. bAccording to immunoreactive score (Remmele and Stegner, 1987).704 S Regele et al
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